Abstract:BackgroundThe use of statin, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor for the treatment of dyslipidemia has been associated with dose limiting hepatoxicity, mytotoxicity and tolerability due to myalgias thereby necessitating the synthesis of new drug candidates for the treatment of lipid disorder.MethodsThe reaction of appropriate benzenesulphonamide with substituted phenoxazinone in the presence of phenylboronic acid gave the targeted compounds. The molecular docking study were carried out using autodock tool against peroxisome proliferator activated receptor alpha. The in vivo lipid profile were assayed using conventional methods. The kidney and liver function test were carried out to assess the effect of the derivatives on the organs. The LD50 of the most active derivatives were determined using mice.ResultsThe targeted compounds were successfully synthesized in excellent yields and characterized using spectroscopic techniques. The results of the molecular docking experiment showed that they were good stimulant of peroxisome proliferator activated receptor alpha. Compound 9f showed activity at Ki of 2.8 nM and binding energy of 12.6 kcal/mol. All the compounds tested reduced triglyceride, total cholesterol, low density lipoprotein cholesterol and very low density lipoprotein cholesterol level in the mice model. Some of the reported compounds also increased high density lipoprotein cholesterol level in the mice. The compounds did not have appreciable effect on the kidney and liver of the mice used. The LD50 showed that the novel compounds have improved toxicity profile.ConclusionThe synthesis of fifteen new derivatives of carboxamides bearing phenoxazinone and sulphonamide were successful. The compounds possessed comparable activity to gemfibrozil. The reported compounds had better toxicity profile than gemfibrozil and could serve as a replacement for the statins and fibrate class of lipid agents.

Design and Synthesis of 3-(2-ethyl-4-{2-[2-(4-fluorophenyl)-5-methyloxazol-4-yl]ethoxy}phenyl)propanoic Acid: A Novel Triple-acting PPARα, -Γ, and -Δ Agonist

Synthesis of a 5-((Aryloxy)methyl)-3-(4-(trifluoromethyl)phenyl)[1,2,4]thiadiazole Derivative: A Promising PPARα,δ Agonist

Synthesis and Evaluation of Novel Α-Heteroaryl-phenylpropanoic Acid Derivatives As PPARα/γ Dual Agonists

Synthesis and evaluation of novel alpha-heteroaryl-phenylpropanoic acid derivatives as PPARalpha/gamma dual agonists.

Design, Synthesis and Biological Evaluation of N,N-3-phenyl-3-benzylaminopropanamide Derivatives As Novel Cholesteryl Ester Transfer Protein Inhibitor

Design, synthesis and PPAR agonist activities of novel L-tyrosine derivatives containing phenoxyacetyl moiety

Virtual identification of novel peroxisome proliferator-activated receptor (PPAR) α/δ dual antagonist by 3D-QSAR, molecule docking and molecule dynamics simulation.

Design, Sythesis And Evaluation Of A Series Of 3-Or 4-Alkoxy Substituted Phenoxy Derivatives As Ppars Agonists

Novel Phenoxazinones as potent agonist of PPAR-α: design, synthesis, molecular docking and in vivo studies

Synthesis and Identification of [1,2,4]thiadiazole Derivatives As A New Series of Potent and Orally Active Dual Agonists of Peroxisome Proliferator-Activated Receptors Alpha and Delta

Tryptophan-Containing Dipeptide Derivatives As Potent Ppar Gamma Antagonists: Design, Synthesis, Biological Evaluation, And Molecular Modeling

Design, Synthesis and Evaluation of PPAR Gamma Binding Activity of 2-Thioxo-4-thiazolidinone Derivatives

Design, Synthesis, and Evaluation of Novel L-Phenylglycine Derivatives As Potential PPARγ Lead Compounds

Design, synthesis, and evaluation of potent novel peroxisome proliferator-activated receptor γ indole partial agonists.

Synthesis And Preliminary Evaluation Of Antidiabetic Activity Of 4-(1-Aryl-3-Aryl/Arylalkyl-3-Oxopropylamino)-N-(5-Methyl-3-Isoxazolyl)Be Nzene Sulfonamide

Scaffold-based Pan-Agonist Design for the PPARα, PPARβ and PPARγ Receptors.

Design and Synthesis of Thiazolidinedione Derivates As Selective Ppar Gamma Modulators

Design, Synthesis, and Biological Evaluation of Novel Pan Agonists of FFA1, PPARγ and PPARδ.

Synthesis of Oleoylethanolamide Analogues

Design,synthesis and bioactivity of 4-[(5-methyl-2-aryloxazol-4-yl) methoxy]benzylene(benzyl)-heterocyclic compounds

Design, synthesis, and evaluation of a new class of noncyclic 1,3-dicarbonyl compounds as PPARalpha selective activators.